Shudong Wang

17PUBLICATIONS
19CO-AUTHORS
Molecular targetsBiologically active moleculesHaematological tumoursCheminformatics and quantitative structure-activity relationshipsProteins and peptides
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 18, 2026
CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

|Oct 29, 2024
Targeting CDK2 to combat drug resistance in cancer therapy.

Sara Kasirzadeh, Jimma Likisa Lenjisa, Shudong Wang

|Apr 13, 2023
Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation.

Biruk Sintayehu Fanta, Jimma Lenjisa, Theodosia Teo

|Feb 25, 2023
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.

Saiful Islam, Muhammed H Rahaman, Mingfeng Yu

|Nov 18, 2022
Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Renjie Chen, Ramin Hassankhani, Yi Long

|Oct 27, 2022
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells.

Saiful Islam, Theodosia Teo, Malika Kumarasiri

Pageof 3

Frequent Collaborators

3 joint publications

Solomon Tadesse

3 joint publications

Hugo Albrecht

3 joint publications

Matthew Sykes

3 joint publications

Mingfeng Yu